MGC Pharma: Pushing the envelope of phytocannabinoid-based research

MGC Pharma: Pushing the envelope of phytocannabinoid-based research
© iStock/Tinnakorn Jorruang

Did you know that MGC Pharmaceuticals is creating a seamless seed-to-pharma pipeline of high-quality, pharmaceutical grade phytocannabinoid-based products?

As the world moves into a new phase of medicines, returning to the human knowledge that has been ignored by science for centuries, the horizon of using phytocannabinoid as treatments is growing wider and wider.

MGC Pharmaceuticals (ASX: MXC; OTC:MGCLF) is at the forefront of the shift – bringing together the scientific world of pharma with the holistic and long-acknowledged benefits of phytocannabinoids to an ever-growing window of indications.

The cannabis plant contains more than 100 phytocannabinoids; the two most well known in today’s world are cannabidiol (CBD) and tetrahydrocannabinol (THC).

MGC Pharma’s core belief in creating a seamless seed-to-pharma pipeline is that every one of those phytocannabinoids has a value that has yet to be fully explored, researched

... read more at: https://www.healtheuropa.eu/phytocannabinoid-based-research/91279/

by